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taken from the 2005 National Inpatient Sample. One-way frequencies, summary sta-
tistics, table analysis, logistic regression, linear regression, and kernel density were all 
used to evaluate the data. We used exploratory data analysis to investigate patient 
outcomes. There were 5622 patients with pneumonia and a control group of 5600
patients. RESULTS: Pneumonia affects 1–2 year olds more than older children. Most 
of the patients had a Charlson number of 0, indicating non-severe conditions. Out of 
5622 patients, there were 73 fatalities. The majority of patients had a hospital expense
of $2,000 to $12,000. Sex did not play a huge factor in the distribution of patient
deaths. The mean age was 7.29 years old. The mean length of stay was 9.41 days. 
Patient procedure and diagnosis codes were analyzed to discover which codes had the
most signiﬁ cant impact on patients, length of stay, and total hospital charges. Patients
with additional diseases were analyzed to see if there was a signiﬁ cant difference in
hospital length of stay and total hospital charges. CONCLUSIONS: Patients have 
different hospital costs, lengths of stay, initial diagnosis, procedures and outcomes
according to their sickness, and how they can be treated. Most patients that come into
the hospital do not have to stay too long, have a moderate hospital expense, and are
generally young children. Pneumonia is a serious illness, occasionally fatal, but it can
usually be treated successfully.
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ECONOMIC ANALYSIS OF MICAFUNGIN VERSUS CASPOFUNGIN 
THERAPY FOR THE TREATMENT OF CANDIDEMIA AND PNEUMONIA 
INFECTIONS
Schaffer K, Schaefer M, Schaefer RS
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OBJECTIVES: The primary objective is to compare candidemia treatment success
between micafungin and caspofungin. Secondary objectives are to identify cost and
mortality rates associated with the use of micafungin versus caspofungin. METHODS:
This was a retrospective chart review of patients who received one dose of micafungin 
or caspofungin during their hospitalization in a regional VA medical center between
January 1, 2004 and February 29, 2008. A combination of electronic data extraction
and manual chart review was performed on each subject’s medical record for patient
characteristics, risk factors, antifungal use prior and post echinocandin, adverse drug
reactions associated with echinocandins, microbiological eradication, clinical success,
length of stay, total hospital cost, and echinocandin cost. All statistical tests were
two-tailed with p-value of less than 0.05 considered statistically signiﬁ cant. RESULTS:
A total of 106 patients with at least one positive bloodstream or sputum culture for 
C. albicans or C. non-albicans were included. Treatment groups had similar baseline
characteristics in all areas except more micafungin patients had renal failure (p 
0.016), prior antifungal use (p  0.021) and post antifungal use (p  0.002). Treatment 
success rates were comparable among groups (74% micafungin compared to 64% 
caspofungin, p  0.279). Microbiological success was 54% vs. 45% (p  0.367) for 
micafungin vs. caspofungin, respectively. There was no difference in microbiological
success between C. albicans and C. non-albicans for micafungin (p  0.802), however, 
a signiﬁ cant difference was seen in the caspofungin patients (C. albicans 35% vs. 59% 
C. non-albicans, p  0.05). Total cost of patient care (p  0.027) and echinocandin 
overall cost (p  0.001) were signiﬁ cantly lower in the micafungin group. Length of 
stay and mortality rates were comparable among groups. CONCLUSIONS: We found
overall treatment success was non-inferior among micafungin and caspofungin 
therapies.
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OBJECTIVES: Achieving sustained virologic response (SVR) could prevent further
transmission of hepatitis C virus (HCV) and reduce chronic hepatitis C (CHC) inci-
dence; we developed a compartment model to describe the dynamics of HCV transmis-
sion in the United States. METHODS: This population model was expressed by partial
differential equations across compartments based on: injection-drug use, CHC infec-
tion, diagnosis, genotypes, treatment/re-treatment, SVR and disease progression.
Model inputs were based on published sources. Model was calibrated from 2002–
2006 and matched closely with CDC reports and other published literature. The cali-
brated model was then applied to assess the CHC burdens from 2007–2040 under 
the current pegylated-interferon/ribavirin (P/R) treatment strategy. A scenario from a
hypothetical new CHC regimen (NEW) was also assessed. This included: NEW avail-
able in 2011 (70% SVR) for genotype-1, treatment-naïve patients; P/R treatment-
failure patients (TFs) re-treated by NEW with 50% SVR; NEW not used to treat
genotype-2/3 patients; P/R durations consistent with current treatment guidelines by
genotypes and costs $28,000/48-week; diagnosis and treatment rates remain unchanged
with NEW. All costs were converted into 2007 dollars using 3% discount rate. 
RESULTS: Under P/R, US CHC prevalence at 2040 is projected to be around 1.7 
million. Overall CHC direct medical cost is about $6 billion a year under P/R, only
13% of which is treatment-related; the remaining 87% comes from managing the
comorbidities and long-term consequences of advanced liver disease (ALD) among 
undiagnosed patients, diagnosed-but-never-treated patients, and TFs. Compared to
P/R, NEW is projected to cure 351,448 more patients, prevent 23,444 more CHC
incidences, avert 103,953 more ALD incidence, and prevent 39,929 more deaths from 
2007–2040. CHC prevalence at 2040 under NEW is projected to be 335,000 fewer 
patients. CONCLUSIONS: A new CHC regimen may have a higher public health 
impact than P/R. Costs unrelated to current CHC treatment with P/R are the major 
burden of hepatitis C.
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OBJECTIVES: The objective of the study was to explore the applicability of pharma-
cogenomics in ART (Antiretro viral therapy). METHODS: Pharmacogenomic studies
in HIV patients were identiﬁ ed from the database of WHO, Pubmed, Clinical trials.
gov and relevant grey literature from 2000–2008. Two reviewers independently 
extracted data. RESULTS: Pharmacogenomics provides a powerful support to inves-
tigate variable responses to antiretroviral therapy. To date, few antiretrovirals appear 
to have a clear genotype–phenotype correlation. However, such correlations have
been demonstrated for CYP2B6 and efavirenz disposition, HLA-B*5701 and abacavir 
hypersensitivity, and UGT1A1 and atazanavir hyperbilirubinemia. Clinically signiﬁ -
cant and conﬁ rmed pharmacogenomic relationships were identiﬁ ed for three ART 
drugs. Out of 405 studies, 6/202 studies were identiﬁ ed as relevant to CYP2B6 and
efavirenz disposition (2RCTs, 1 nRCT and 3 pharmacokinetic studies). Three (3/118) 
studies were identiﬁ ed for HLA-B*5701 and abacavir hypersensitivity (2 RCTs and 1
nRCT) and 2/85 studies for UGT1A1 and atazanavir hyperbilirubinemia (1RCT and 
1nRCT). Studies (2/6) revealed that genotype and sex were identiﬁ ed as predictive 
covariates of efavirenz disposition. Studies (2/3) across the world have consistently 
demonstrated that HLA-B*5701 predicts the likelihood of hypersensitivity reactions
to abacavir. As a consequence, pharmacogenetic screening for HLA-B*5701 has
entered routine clinical practice and is recommended in most guidelines before starting 
an abacavir containing regimen. Studies (1/2) show that polymorphisms at MDR1-
3435 signiﬁ cantly inﬂ uence atazanavir plasma concentrations, although ATV plasma 
concentrations directly correlate with bilirubin levels, the risk of severe hyperbilirubi-
nemia is further increased in the presence of the UGT1A1-TA7 allele. CONCLU-
SIONS: Although the wider applicability of pharmacogenomic relationships is 
prevalent and its use in clinical practice is still limited. Pharmacogenomics can greatly 
contribute in taking more adequate therapeutic decisions and to optimise treatment 
for HIV/AIDS.
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OBJECTIVES: The human papillomavirus is the most common sexually transmitted 
disease in America. This virus will affect 6.2 million Americans this year. Most cases 
of HPV come from sexual contact or vaginal delivery from an infected mother. It is the 
objective of this study to gain more knowledge about HPV in order to be able to control
or prevent the spreading of this virus. METHODS: A data set of over 22,000 pediatric
patients from the 2005 National Inpatient Sample was used for analysis with SAS 
Enterprise Guide to examine different characteristics of HPV. From SAS, we were able 
to set up one way frequencies, pie charts, kernel densities, and logistic and linear
regressions to compare and contrast different aspects of HPV. We also examined patient 
diagnosis and procedure codes. RESULTS: The most prominent age groups affected 
by HPV are young children and adolescents. This is a concern since there is a strong 
relationship to cervical cancer in later life. Although two types of the virus (16 and 18)
are responsible for 70% of cervical cancers, less than 1% of the patients in our sample 
died with HPV. This virus is not costly to detect or treat with the majority of the patients 
charged around $5,000 from hospitalization with the virus. We found that 90% of 
patients with a URI also had HPV. We found many statistically signiﬁ cant relationships 
between demographics, procedures, and diagnoses, and length of stay or total charges 
of the patient. CONCLUSIONS: Further research is still needed for doctors to be able 
to prevent or cure HPV. Trial medications are out on the market targeting young
females, but surprisingly, more males have HPV because they are the carriers of this 
virus. We need to focus more time and money to ﬁ nd a cure for HPV.
PIN7
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OBJECTIVES: Cellulitis is a skin infection caused by bacteria. In children, cellulitis 
most often occurs on the face, legs, arms, or around the area near the anus. It can 
usually be treated with antibiotics (oral or topical). However, if not treated, the infec-
tion can spread and cause far more serious conditions such as meningitis or blood clots
in the legs. The objective of this paper is to explore the data of pediatric patients who 
have cellulitis and to compare the results to patients who do not have the disease. Basic
variables such as age, race, and gender are examined along with recorded patient 
diagnosis and procedure codes. METHODS: The statistical software SAS was used to
analyze and explore the data supplied by the National Inpatient Sample for 2005. The
dataset contained 1287 patients with cellulitis and a control group of 1300 without 
cellulitis. Statistical methods used include one-way frequencies, kernel densities,
summary statistics, table analyses, logistic regression, and linear regression. We also 
examined the most frequent patient diagnoses and procedures for the patients in the 
dataset. RESULTS: The patients represented by the data are all pediatric. About 63% 
of patients with cellulitis are male, with about 37% female. The age group with the 
highest concentration of patients is 0–3 with about 29% of the total. Only 0.08% of 
the patients with cellulitis actually died. In general, the disease is not fatal. The average 
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length of stay in the hospital is about 3.5 days. CONCLUSIONS: After the logistic and
linear regressions, the results showed a small correlation with cellulitis. The likelihood 
of having a bacterial infection or having infections with microorganisms increases with 
cellulitis. The likelihood of having a venous catheterization, having the skin drained,
or having the tendon sheath of the hand explored increases with cellulitis.
INFECTION – Cost Studies
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THE ECONOMIC IMPACT OF TRANSITIONING VALACYCLOVIR TO OVER
THE COUNTER STATUS FOR THE TREATMENT OF GENITAL HERPES
Chang JY, Nichol MB
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OBJECTIVES: Genital herpes affects more than 45 million individuals in the United 
States with an estimated 400,000 physician ofﬁ ce visits each year for primary infec-
tions. With no cure for the herpes infection, it can be transmitted from the infected 
individuals to the unsuspecting population throughout the lifetime of the infected.
With the approaching patent expiration for the prescription drug valacyclovir 
(Valtrex) in 2009, this study examines the implications of transitioning valacyclovir 
to an over the counter (OTC) status. METHODS: A decision analysis model was used
to examine the current prescription based requirement for valacyclovir compared to 
the OTC status for the product. The analysis was constructed from a societal perspec-
tive using a budget impact model. A simulation model conducted in a hypothetical 
cohort of 10,000 individuals with primary genital herpes in the United States with 
direct medical cost as the principal outcome. Cost estimations are based on literature 
review and national health care databases. A sensitivity analysis through a Monte 
Carlo simulation will assess the validity of the cost estimates. RESULTS: The transition 
of valacyclovir to OTC status will amount to an average annual savings of $707 
($544–$868) per newly infected individual in the form of direct medical expenditures. 
The annual average cost for the OTC transition is $108 per newly infected, compared
to the annual average cost of the prescription based requirement of $815 per newly
infected. Aggregate annual savings to the United States from newly infected individuals 
is $282 million per year. CONCLUSIONS: Transitioning valacyclovir to OTC status 
is a cost saving measure for society, largely due to the decrease in physician ofﬁ ce visits 
for valacyclovir prescriptions. Further studies will need to address speciﬁ c population 
needs in regards to herpes education, feasibility of self-diagnosis, viral resistance and
indirect cost.
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OBJECTIVES: Studies in Mexico have shown that the health expenditure attributed
to antirretroviral treatments for naïve and experimented patients is high. This has an 
impact on the national budget of the public health institutions, especially for units
from the Ministry of Health which deal with the largest number of HIV/AIDS cases
in the country. The objective of this analysis was to estimate the ﬁ nancial impact of 
increasing the availability of atazanavir for the treatment of patients with HIV/AIDS 
in the MoH institutions. METHODS: A budgetary impact model based on epidemio-
logical data, treatment costs and market uptake for four proteasa inhibitors (PI) in a 
time horizon of ﬁ ve years was developed. A baseline scenario, where the current 
PIs market distribution remains the same, was compared with a scenario where 
atazanavir availability is increased. RESULTS: The estimated numbers of infected
HIV/AIDS subjects will grow around 53.48% in the next ﬁ ve years. As a result,
more resources will be needed to face the increasing burden of the disease. The com-
parisons between the two scenarios show that the estimated budget impact related to 
the acquisition of PI is cost-saving. The estimated savings in 2009 are of US$1.168 
million increasing 3.4 times during the ﬁ ve years period. Savings from the treatment 
of main side effects such as, diarrhea and cholesterol lowering intervention are also
observed (US$ 12,777 and US$17,861 in 2009 respectively). CONCLUSIONS: An 
increase in the utilization of atazanavir represents a good clinical and economic option
for the Mexican MoH in the short and long run. The highest impact in the budget
is produced mainly by the pharmacological costs. However, budget savings are also 
derived from the reduction of treatment costs side effects such as diarrhea and
hypercholesterolemia.
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BUDGET IMPACT OF ANTIMALARIA DRUG FORMULARY DECISIONS: 
A RETROSPECTIVE ANALYSIS FROM A NIGERIAN TEACHING HOSPITAL
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OBJECTIVES: To quantify the Budget Impact of antimalaria drug formulary decisions
in a Nigerian Teaching Hospital. METHODS: A retrospective random sample of 
17,000 prescriptions (2001–2008) with the wholesale prices of each prescribed drug 
was collected from pharmacy records. The total number of prescriptions per day, the
date and the therapeutic class of the prescribed drugs were also noted. From this data,
estimates of the proportion of patients that received a particular antimalaria medicine 
and the year of introduction or deletion of the drug from the drug formulary were
made. The costs of a complete dose required for the treatment of a patient suffering
from malaria when prescribed a given antimalaria drug were calculated from the 
extracted wholesale prices. These variables served as input in a stochastic Monte Carlo
model which was built to simulate the Budget Impact of each identiﬁ ed formulary 
decision by subtracting the total cost of drugs in the Old Drug Scenario from that of 
the New Drug Scenario. Negative values represent cost savings. A sensitivity analysis 
was conducted by varying the input parameters by o 50%. RESULTS: Halofantrine 
was introduced into the hospital formulary in 2002 with a resultant signiﬁ cant (p 
0.0001) savings of NGN1.02million with a mean of NGN0.16million. The introduc-
tion of arthemisinin combination therapies (ACTs) in 2005 with the addition of IM 
arthemether in 2007 led to an increase expenditure of NGN3.02million (p  0.0001) 
and NGN0.07million (p  0.171) respectively. In 2008, the number of patients that 
were prescribed ACTs decreased from 80.9% in 2007 to 67.9%. This strategy pro-
duced a cost saving of NGN6.27million which was signiﬁ cant (p  0.0001). Sensitivity 
analysis conﬁ rmed the robustness of the model. CONCLUSIONS: Introduction of 
ACTs into the hospital drug formulary signiﬁ cantly increased drug expenditure. We 
therefore suggest that a CEA of available antimalarials may prove to be a valuable 
tool to this budget holder.
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COMPLICATED SKIN AND SOFT TISSUE INFECTIONS (CSSTI): 
A COMPARISON OF LINEZOLID, VANCOMYCIN, DAPTOMYCIN, 
AND TIGECYCLINE
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OBJECTIVES: Previous economic analyses of MRSA-conﬁ rmed cSSTI have not 
included costs related to outpatient parenteral antibiotic therapy (OPAT). The objec-
tive of this analysis was to develop an economic model to estimate medical and 
drug costs within both inpatient and outpatient components of care for treating
MRSA cSSTI. METHODS: A 4-week decision model was developed to estimate the 
direct total, inpatient, and outpatient costs of treating MRSA cSSTI from a U.S. payer 
perspective taking into account successes, failures, and adverse events (AEs). Com-
parators included vancomycin, linezolid, daptomycin, and tigecycline. Published 
literature and database analyses, with validation by experts, provided clinical inputs
and resource use data including MRSA efﬁ cacy, length of stay (LOS), consequences 
of AEs and cSSTI failure, OPAT services, among others. Cost data was derived
from literature and standard CPT coding reimbursements. The base case analysis 
assumed equal efﬁ cacy and equal LOS of 4 days among comparators. Univariate and 
probabilistic sensitivity analyses tested efﬁ cacy, complication rates, LOS, and other
resource use parameters. Costs were reported in 2008US$. RESULTS: Total drug 
acquisition costs were 4–6 times lower for vancomycin compared to tigecycline, 
linezolid, and daptomycin. However, the total 4-week cost of treatment including 
drugs, clinical failures, complications, and OPAT were lowest for linezolid ($8,149), 
followed by vancomycin ($8,974), tigecycline ($10,333), and daptomycin ($11,362). 
Oral linezolid reduced the outpatient medical costs by 10-fold versus IV comparators.
The most sensitive model variables for total cost were the MRSA efﬁ cacy, hospital
LOS, OPAT days, and line placement/complication costs. CONCLUSIONS: Although 
total drug acquisition costs were lower for vancomycin vs. comparators, the model
suggests linezolid provides total cost savings in cSSTI versus IV therapies, particularly
in the outpatient arena. The budget impact of antimicrobials for cSSTI should consider
total medical cost offsets from both inpatient and outpatient perspectives.
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INFECTION (CSSSI) USING A DECISION ANALYTIC MODEL
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OBJECTIVES: To evaluate the cost-effectiveness of daptomycin versus vancomycin in
complicated skin and soft structure infections (cSSSI). METHODS: A decision analytic 
(DA) model was developed to evaluate the cost-effectiveness of daptomycin versus
vancomycin in cSSSI. The payer perspective was adopted and total direct costs related
to cSSSI were measured. Efﬁ cacy (cure) was deﬁ ned as a patient who was treated
empirically with the study drug, had a positive culture of Methicillin-resistant Staphy-
lococcus aureus did not relapse at the test of cure. Previous literature was used to 
determine the parameters of the model. Costs were determined from 2008 Drug Red 
Book and Decision Support System database. Primary outcome was the incremental
cost-effectiveness ratio (ICER) of daptomycin over vancomycin. One-way sensitivity
analyses was performed for all parameters and presented in a tornado diagram. 
Probabilistic sensitivity analysis was performed on all parameters using 10,000 trial
simulations. RESULTS: In the base-case analysis, daptomycin and vancomycin arms 
had total direct costs of $11,162.88 and $16,307.74, respectively. Cure probabilities
for patients in the daptomycin and vancomycin arms were 51.6% and 40.2%, respec-
tively. Cost-effectiveness ratio for daptomycin and vancomycin were $21,619.78/cure 
